Organisation paid for research Program year 2025 Source: CMS Open Payments

Meridien Research

Neither a doctor nor a teaching hospital

Research payments

$5,850,651

808 payments

Through program year 2025, Meridien Research is reported as receiving $5,850,651 in research payments, across 808 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$2,530	5
2024	Research	$8,684	6
2023	Research	$107,419	21
2022	Research	$134,819	20
2021	Research	$325,243	55
2020	Research	$930,173	212
2019	Research	$4,341,781	489

Breakdown

Who paid Research payments · program years 2019–2025

Tris Pharma Inc $1,093,353 13 payments
Adlon Therapeutics L.P. $1,007,635 39 payments
Allergan Inc. $836,757 133 payments
AbbVie, Inc. $595,582 162 payments
Supernus Pharmaceuticals, Inc. $558,962 60 payments
Novartis Pharmaceuticals Corporation $359,612 15 payments
Biogen, Inc. $280,623 3 payments
Novo Nordisk AS $251,941 82 payments
Eli Lilly and Company $192,551 77 payments
Sage Therapeutics, Inc. $134,709 44 payments

Studies the money was for Research payments · program years 2019–2025

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD $1,093,353 13 payments
063-020 $1,012,408 43 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $447,886 68 payments
M16-100 $415,564 98 payments
A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $290,967 19 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of Spn-812 in Adults With Attention-Deficit/Hyperactivity Disorder (Adhd) $270,193 17 payments
A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $263,810 2 payments
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Spn-812 in Adults With Attention- Deficit/Hyperactivity Disorder $261,968 30 payments
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $156,137 1 payment
M16-283 $138,966 34 payments

What the money was spent on Research payments · program years 2019–2025

Other $1,750 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.